Upcoming Webinars

“Using PBPK modeling to assess the impact of diseases on oral drug absorption: a tale of 2 drugs”

Wednesday, June 29, 2022
5 AM CEST (Paris) / 8 AM PT (Los Angeles) / 11 AM ET (New York)

Randomized clinical trial is the most effective way to determine whether a cause-and-effect relationship exists between an intervention and a predefined clinical outcome. Much attention has been paid to the internal validity of a clinical trial, i.e. the extent to which the design and conduct of a trial eliminates the possibility of bias. In this webinar, we will go over two case studies leveraging IVIVE-PBPK modeling to prospect the impact of HIV and cystic fibrosis on the oral absorption of two broadly prescribed BCS 2 drugs.

Dr. Rodrigo Cristofoletti
Assistant Professor, Center for Pharmacometrics & Systems Pharmacology, Dept. of Pharmaceutics
University of Florida

Register Here

“Predicting pharmacokinetics of multisource acyclovir oral products through Physiologically Based Biopharmaceutics Modeling”

Wednesday, July 13, 2022
5 AM CEST (Paris) / 8 AM PT (Los Angeles) / 11 AM ET (New York)

Highly variable disposition after oral ingestion of acyclovir has been reported, although little is known regarding the underlying mechanisms. Different studies using the same reference product (Zovirax ®) showed that Cmax and AUC were respectively 44 and 35% lower in Saudi Arabians than Europeans, consistent with higher frequencies of reduced-activity polymorphs of the organic cation transporter (OCT1) in Europeans. This webinar will explore this study in depth.

Dr. Peter Langguth, University Professor at Johannes Gutenberg University Mainz
Dr. Mauricio A. Garcia, PhD student/Research Assistant, Johannes Gutenberg University Mainz

Register Here


Watch Past Webinars

ADMET Predictor® 10.2 (APX.2): Machine learning platform for ADMET modeling with extended capabilities for discovery PBPK

Stream Download

DILIsym® Applications in Drug Development – Perspectives from 2 Pharma Industry Executives & an Experienced Consultant

What do NURTEC™ ODT, TURALIO®, lixivaptan, solithromycin, JYNARQUE®, VEKLURI®, and UBRELVY® have in common?


Modeling and Simulation of a parent-metabolite-PD datatset (Spring School challenge solution)

Whether you have participated to our Spring School and its modeling challenge or not, this webinar is for you!


Human-on-a-Chip combined with PBPK modeling for in vitro/in vivo PK/PD extrapolation

Human-on-a-Chip (HoaC) systems are becoming valuable tools to study, understand disease physiology, and expand the prediction of pharmacodynamic effects before first-in-human studies. They can also be used to evaluate the toxic effects of compounds in non-pharma industries where these effects cannot be examined in vivo.

Stream Download

Early assessment of PK properties using ADMET Predictor® HTPK Simulation Technology

Physiologically-based pharmacokinetic (PBPK) modeling, combined with in vitro and in vivo extrapolation (IVIVE) approaches...

Stream Download

AAPS Webinar: Translating manufacturing variants from in vitro to the clinic. Opportunities and gaps for IR formulations with additional IVIVC ‘Safe Space’ applications

Development of an in vitro/in vivo correlation (IVIVC) can be most challenging for immediate release (IR) products

Stream Download

New Library of Tumor Growth Inhibition Models in Monolix

Presentation of the models in the TGI library available in Monolix and Simulx


GastroPlus® v9.8.1 DDI Standards Update and Documentation Project

This webinar will be an introduction to the "GastroPlus DDI Standards Update" project.

Stream Download

IPFsym™, a platform to support the development of effective treatments for IPF patients

Patients with idiopathic pulmonary fibrosis (IPF) have a low survival prognosis and limited treatment options.

Stream Download

Strategic Implementation of Model-informed Drug Development (MIDD) for Regulatory Success

In honor of the International Day of Women and Girls in Science, she will also share and reflect on some of her early career experiences.